FR EA

Extract to table

Pull the structured facts out of a document: parties, dates, amounts, obligations.

Extract to table / schedule-d-territory.docx
schedule-d-territory.docx · 1018-00006

Parties

Penterra Pharmaceuticals Corp
Hong Kong SA
Macau SA

Dates

October 2, 2023
October 20, 2023

Amounts

—

Obligations

Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement
For all purposes under the Agreement, references to the People's Republic of China in this Schedule D and throughout the Agreement shall be deemed to include the Hong Kong Special Administrative Region ("Hong Kong SAR") and the Macau Special Administrative Region ("Macau SAR")
Separate regulatory filings, pricing approvals, or import licenses required in Hong Kong SAR or Macau SAR under their respective local laws shall be the responsibility of Licensee in accordance with Article 4 of the Agreement
Any expansion of the Territory to include additional countries or jurisdictions not listed in Section 2 above, or any modification of the boundaries or scope of the Territory, shall require a written amendment to the Agreement duly executed by authorized representatives of both Licensor and Licensee
No course of dealing, verbal agreement, or other conduct by either Party shall be construed as an expansion or modification of the Territory absent such a written amendment
In the event Licensee wishes to request the inclusion of one or more additional jurisdictions in the Territory, Licensee shall submit a written proposal to Licensor that includes a commercially reasonable development and commercialization plan for the Licensed Product in each such proposed jurisdiction, and the Parties shall negotiate in good faith the terms and conditions, including any additional milestone payments, royalty rates, and development timelines, upon which such expansion would be granted, it being understood that Licensor shall have no obligation to agree to any such expansion